The Future of R&D Outsourcing

Current industry trends are examined as the context of This report summarizes the current landscape for outsourcing in the pharmaceutical industry, identifying emerging trends and predicting important models for the future. A review of traditional and emerging working relationships between pharma and CRO are also presented.

Features and benefits

• Understand different sponsor/CRO working models currently practiced.
• Identify emerging and future trends in the outsourcing market.
• Understand the benefits of innovative partnership arrangements between pharma and CRO.
• Identify the services of greatest importance in the outsourcing market.
• Forecast the CRO market to 2016.

Highlights

The use of outsourcing has developed over the last 10 years from a tactical commodity exchange to a full strategic partnership involving sharing of goals and objectives, milestones, knowledge, processes, and in some cases, risks. This trend is predicted to continue over the coming 5–10 years.

Offering drug discovery and preclinical research facilities supports full-service CROs in their position as sole providers for large pharmaceutical companies. The global market in drug discovery and preclinical outsourcing is expected to continue to show strong growth over the short to medium term.

CROs are leading the field in the development of innovative solutions to improve clinical trial efficiency, including the use of adaptive design trials. Adaptive design improves efficiency by reducing waste and shortening timelines.

Your key questions answered

• What models of outsourcing will dominate over the next 5 to 10 years?
• How can manufacturers and CROs work together more effectively to accelerate drug development?
• How can manufacturers and CROs work together more effectively to accelerate drug development?
• Which parts of the R&D process are best suited to outsourcing?
• Which group of outsourcing providers will face the toughest conditions to 2017?

Buy your copy of this report @ http://www.reportsnreports.com/reports/179865-the-future-of-rd-outsourcing.html

 Table of Contents

About the author
Disclaimer

EXECUTIVE SUMMARY
Introduction
Emerging outsourcing strategies
The future of drug discovery and preclinical outsourcing
The future of clinical outsourcing

Introduction
Summary
Introduction
A crisis in innovation
A challenging time for pharma
Loss of patent protection
Inadequate product pipelines
Increasing complexity of drug development process
Saturation of easy-access products
Rise of biological products
Increasing regulatory scrutiny
Global economic crisis
Strategic solutions to the industry crisis
Increased R&D spending
Consolidation
Biotech in-licensing
R&D reorganization
Outsourcing
Rise of outsourcing
Benefits of outsourcing

Emerging outsourcing strategies
Summary
Introduction
Strategic models by degree of integration
Transactional (project-by-project) approach
Preferred provider
Partnership
Strategic alliance (risk-sharing)
Full integration
Service provision
Full-service outsourcing
Functional service providers
Niche outsourcing
Relationship management
Managing successful relationships
Exit strategies

The future of drug discovery and preclinical outsourcing
Summary
Introduction
Drug discovery outsourcing
Market drivers in drug discovery outsourcing
Limitations of drug discovery outsourcing
Factors for success in drug discovery outsourcing
Preclinical outsourcing
Preclinical outsourcing market
Preclinical outsourcing trends

The future of clinical outsourcing
Summary
Introduction
Traditional outsourced clinical services
New model of clinical development
New ways of conducting clinical trials: adaptive design